2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
77
Neoplasms
69
Prostatic Neoplasms
51
Colorectal Neoplasms
44
Lung Neoplasms
38
Carcinoma, Non-Small-Cell Lung
28
Hematologic Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Head and Neck Neoplasms
19
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
15
Multiple Myeloma
15
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Glioblastoma
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Gastrointestinal Neoplasms
9
Colonic Neoplasms
9
Melanoma
8
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Interventions
Blood Specimen Collection
29
Reverse Transcriptase Polymerase Chain Reaction
7
Flow Cytometry
7
Surgical Procedures, Operative
4
Liquid Biopsy
4
cabazitaxel
3
Trastuzumab
3
Propofol
3
Carboplatin
3
Bevacizumab
3
Standard of Care
2
Spinal Puncture
2
Sevoflurane
2
Positron Emission Tomography Computed Tomography
2
Pirinitramide
2
Neoadjuvant Therapy
2
Morphine
2
Laparoscopy
2
Hematologic Tests
2
Gemcitabine
2
Folfox protocol
2
Epirubicin
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
Aspirin
2
Anesthesia, General
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplastic Cells, Circulating
×
Standard of Care
×
Clear all
NCT06391892
2024-04-30
LIQUIPANC
Elisabethinen Hospital
Phase 3
Recruiting
100 enrolled
NCT01129336
2014-05-20
MACS1295
Novartis
Phase 4
Completed
44 enrolled
10 charts